Loading...
Loading...
Neuralstem, Inc.
CUR announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Patient 13 is the first in the trial to be dosed in this region.
It is also the first time surgeons have gone into the gray matter of the cervical region. The initial twelve patients in the trial all received stem cell transplants in the lumbar (lower back) region of the spinal cord only.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in